ATE489963T1 - Chaperonin-10-immunosuppression - Google Patents

Chaperonin-10-immunosuppression

Info

Publication number
ATE489963T1
ATE489963T1 AT03769073T AT03769073T ATE489963T1 AT E489963 T1 ATE489963 T1 AT E489963T1 AT 03769073 T AT03769073 T AT 03769073T AT 03769073 T AT03769073 T AT 03769073T AT E489963 T1 ATE489963 T1 AT E489963T1
Authority
AT
Austria
Prior art keywords
donor
recipient animal
cpn10
administration
host disease
Prior art date
Application number
AT03769073T
Other languages
English (en)
Inventor
Geoffrey R Hill
Tatjana Banovic
Halle Morton
Alice Christina Cavanagh
Original Assignee
Cbio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cbio Ltd filed Critical Cbio Ltd
Application granted granted Critical
Publication of ATE489963T1 publication Critical patent/ATE489963T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Glass Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03769073T 2002-11-06 2003-11-06 Chaperonin-10-immunosuppression ATE489963T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2002952492A AU2002952492A0 (en) 2002-11-06 2002-11-06 Chaperonin 10 immunosuppression
PCT/AU2003/001467 WO2004041300A1 (en) 2002-11-06 2003-11-06 Chaperonin 10 immunosuppression

Publications (1)

Publication Number Publication Date
ATE489963T1 true ATE489963T1 (de) 2010-12-15

Family

ID=28795882

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03769073T ATE489963T1 (de) 2002-11-06 2003-11-06 Chaperonin-10-immunosuppression

Country Status (16)

Country Link
US (3) US7618935B2 (de)
EP (3) EP2818179A1 (de)
JP (2) JP4716731B2 (de)
KR (1) KR101088740B1 (de)
CN (1) CN100525832C (de)
AT (1) ATE489963T1 (de)
AU (1) AU2002952492A0 (de)
CA (1) CA2505141C (de)
CY (1) CY1110972T1 (de)
DE (1) DE60335202D1 (de)
DK (1) DK1569679T3 (de)
ES (1) ES2351993T3 (de)
NZ (1) NZ540433A (de)
PT (1) PT1569679E (de)
SI (1) SI1569679T1 (de)
WO (1) WO2004041300A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005204979B2 (en) * 2004-01-16 2010-10-21 Cbio Limited Chaperonin 10 modulation of toll-like receptor-inducible cytokine and chemokine secretion
NZ548985A (en) * 2004-01-16 2010-02-26 Cbio Ltd Chaperonin 10 modulation of toll-like receptor-inducible cytokine and chemokine secretion
US8036710B2 (en) * 2004-05-07 2011-10-11 Qualcomm, Incorporated Power-efficient multi-antenna wireless device
AU2006269824B2 (en) * 2005-07-11 2012-04-19 Cbio Limited Chaperonin 10-induced immunomodulation
MX2008000596A (es) * 2005-07-11 2008-03-19 Cbio Ltd Inmunomodulacion inducida por la chaperonina 10.
NZ566817A (en) * 2005-08-31 2012-02-24 Cbio Ltd Modified chaperonin 10, wherein the N-terminus comprises a single additional glycine residue compared to a corresponding mammalian wild-type
EP1951282A4 (de) * 2005-10-20 2009-09-02 Cbio Ltd Behandlung von überempfindlichkeit
AU2006303826B2 (en) * 2005-10-20 2012-07-19 Cbio Limited Treatment of hypersensitivity
CA2644058C (en) 2006-03-02 2016-08-09 Cbio Limited Regulation of immune responses by modulation of the function of antigen presenting cells
WO2009124353A1 (en) * 2008-04-11 2009-10-15 Cbio Limited Modified cpn10 and prr signalling
US20110243921A1 (en) * 2010-03-30 2011-10-06 Cbio Limited Prevention and treatment of cutaneous lupus erythematosus
WO2013158959A1 (en) * 2012-04-19 2013-10-24 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of graft-versus-host disease
US9688741B2 (en) 2012-10-23 2017-06-27 Elastagen Pty Ltd Elastic hydrogel
RU2668877C2 (ru) 2012-12-10 2018-10-04 Эластаджен Пти Лтд, Масштабируемое получение трехмерных эластичных конструкций
JP6382311B2 (ja) 2013-08-13 2018-08-29 エラスタジェン・プロプライエタリー・リミテッドＥｌａｓｔａｇｅｎ Ｐｔｙ Ｌｔｄ 損傷組織の再生

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2176948C (en) * 1993-11-30 2007-05-15 Halle Morton Chaperonin 10
PT731811E (pt) * 1993-11-30 2005-04-29 Univ Queensland Chaperonina 10
US5989804A (en) * 1994-07-08 1999-11-23 New England Medical Center Hospitals, Inc. E6 binding proteins
JPH11510806A (ja) * 1995-08-09 1999-09-21 シェーリング コーポレイション 免疫抑制治療のためのインターロイキン１０およびシクロスポリンの併用
US20020142000A1 (en) * 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
EP1218030A4 (de) * 1999-09-10 2004-09-15 Univ Fordham Methoden und zusammensetzungen zur behandlung und prävention von transplantatabstossung durch verwendung von hitzeschockproteinen
GB0028122D0 (en) * 2000-11-17 2001-01-03 St Georges Entpr Ltd Method

Also Published As

Publication number Publication date
US8067361B2 (en) 2011-11-29
DE60335202D1 (en) 2011-01-13
CA2505141A1 (en) 2004-05-21
CN100525832C (zh) 2009-08-12
EP2818179A1 (de) 2014-12-31
AU2002952492A0 (en) 2002-11-21
EP1569679B1 (de) 2010-12-01
EP2255824B1 (de) 2014-07-23
US20100099605A1 (en) 2010-04-22
NZ540433A (en) 2008-03-28
PT1569679E (pt) 2010-12-14
EP1569679A4 (de) 2008-02-27
US7618935B2 (en) 2009-11-17
CN1735428A (zh) 2006-02-15
JP2006508099A (ja) 2006-03-09
CA2505141C (en) 2012-07-17
WO2004041300A1 (en) 2004-05-21
JP4716731B2 (ja) 2011-07-06
KR20050086428A (ko) 2005-08-30
EP2255824A1 (de) 2010-12-01
KR101088740B1 (ko) 2011-12-01
JP2011088920A (ja) 2011-05-06
EP1569679A1 (de) 2005-09-07
US20120082690A1 (en) 2012-04-05
SI1569679T1 (sl) 2011-01-31
ES2351993T3 (es) 2011-02-14
DK1569679T3 (da) 2011-01-10
CY1110972T1 (el) 2015-06-11
US20060198834A1 (en) 2006-09-07

Similar Documents

Publication Publication Date Title
CY1110972T1 (el) Ανοσοκαταστολη με σαπερονινη 10
CO5700767A2 (es) Procedimiento de tratamiento de rechazo de transplantes
CY1116107T1 (el) Ενωσεις για χρηση στην αγωγη αυτοανοσων παθησεων, ανοσο-αλλεργικων παθησεων και απορριψης μεταμοσχευσης οργανων ή ιστων
BR0203650A (pt) Estentor de auto-articulação
EP1676574A3 (de) Verfahren zur Förderung des Überlebens von Zell- und Gewebe-Transplantaten
DE60330468D1 (de) Schweine ohne jegliche expression funktioneller alpha-1,3-galactosyltransferase
ATE463256T1 (de) Mittel zur suppression von transplantat- abstossung
DK1487431T3 (da) Forebyggelse og/eller behandling af cardiovaskulær sygdom og/eller dermed associeret hjertefejl
NO20052505L (no) Ny bruk av dextran-sulfat
WO2004039248A3 (en) Repairing or replacing tissues or organs
WO2004091436A3 (en) Methods and compositions for treating ocular disease
WO2003102162A3 (en) Novel tolerogenic dendritic cells and therapeutic uses therefor
WO2005041877A3 (en) Method of inhibiting rejection following organ transplantation
HK1060855A1 (en) Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment ofdelayed graft function
WO2005058280A3 (en) Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
MXPA05004121A (es) Metodos para tratar la enfermedad de ojo reseco con lantibioticos.
BG104259A (en) Derivatives of 4-cyano-4-deformylsordaricin
AU2202301A (en) Cd45 inhibitors
DE69815355D1 (de) 4-cyano-4-deformylsordarinderivate
NO20016326D0 (no) Anvendelse av proteinet UK 114 for å hindre avstötning av organtransplantatet
HUP0103107A2 (hu) Allogénikus és xenogénikus T-sejtek ex vivo kezelése gp39 antagonistákkal
RU2004128515A (ru) Способ восстановления кожного покрова при комбинированных радиационно-ожоговых поражениях

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1569679

Country of ref document: EP